Department of Radiation Oncology, Summa Comprehensive Cancer Institute, Akron, OH 44304, USA.
Curr Opin Oncol. 2013 Sep;25(5):532-8. doi: 10.1097/CCO.0b013e328363e0ad.
This current work offers an opinion on the evidence accumulated in humans regarding stereotactic ablative radiation (SABR) therapy, a favorable option for the treatment of persistent or recurrent metastatic gynecologic cancers.
SABR precisely and accurately kills cancer cells, making durable disease control possible. This article evaluates SABR's clinical performance and the variations in the main components of SABR technology, such as target localization and radiation beam collimation coupled with respiratory motion tracking, in the context of their contribution to the banked clinical successes in gynecologic radiation oncology.
In an era of patient requests for short radiotherapy courses, SABR now provides well tolerated and efficacious treatment for women with gynecologic cancers.
本研究就立体定向消融放疗（SABR）治疗持续性或复发性妇科转移性癌症这一有利选择的人体相关证据提供了观点。
SABR 可精确且准确地杀死癌细胞，从而实现持久的疾病控制。本文评估了 SABR 的临床疗效，以及 SABR 技术的主要组成部分（如目标定位和辐射束准直与呼吸运动跟踪）的变化，探讨了它们对妇科放射肿瘤学中 SABR 成功治疗的贡献。
在患者要求短程放疗的时代，SABR 为妇科癌症患者提供了可耐受且有效的治疗。
